WALTHAM, Mass.--(BUSINESS WIRE)--Oscient Pharmaceuticals Corporation (Nasdaq: OSCI) will participate in the Roth Capital Partners 20th Annual OC Growth Conference on Thursday, February 21, 2008 in Dana Point, California. The Company’s President and CEO, Steven Rauscher, will provide an overview of the Company; highlight details on the recent market performance of ANTARA® (fenofibrate) capsules and FACTIVE® (gemifloxacin mesylate) tablets in the U.S.; and discuss the Company’s recently announced results for fiscal year 2007, in which Oscient recorded $80.0 million in revenues.
